Human Genome Sciences

(HGSI)

said Monday that H. Thomas Watkins has been appointed CEO, as well as a member of the company's board.

Watkins, 51, who recently served as president of TAP Pharmaceutical Products, which is jointly owned by

Abbott Laboratories

(ABT) - Get Report

and Japan's Takeda Pharmaceutical, succeeds William A. Haseltine, the company's founder and former chairman and CEO, who retired Oct. 17.

Maryland-based Human Genome Sciences tries to treat and cure disease by creating gene-based protein and antibody drugs.

At one point during the heyday of the last bull market, it traded at more than $200 a share, or $100 on a split-adjusted basis. Shares ended at $10.47 Friday.

For the nine months ended Sept. 30, revenue decreased 15% to $3 million, while its net loss increased 29% to $176.2 million.